Status:
RECRUITING
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
Lead Sponsor:
Peking University Third Hospital
Conditions:
Stereotactic Body Radiation Therapy
Irradiation; Reaction
Eligibility:
All Genders
18-80 years
Brief Summary
The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effect...
Eligibility Criteria
Inclusion
- Pathological diagnosis is malignant tumor.
- The location of the target lesion belongs to the ultra-central type of chest.
- The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm.
- There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.
- KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.
Exclusion
- Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.
- The general condition is poor, and the expected survival time is less than 3 months.
- Psychiatric patients or poor compliance, unable to cooperate to complete treatment.
- For other reasons, the researcher believes that it is not suitable to participate in this trial.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2027
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05189054
Start Date
May 1 2022
End Date
April 30 2027
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191